Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma. H…
UK Drug Safety Update · April 24, 2025
Short-acting beta 2 agonists (SABA): reminder of risks from overuse in asthma and changes to prescribing guidelines
Original title: Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Healthcare professionals and patients reminded of risks of severe asthma attacks and increased mortality from SABA overuse, with updated prescribing guidance.
Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.